Pharmaceutical Technology

JULY 7, 2023

ABBV-101 is under clinical development by AbbVie and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL).

52

52

Pharmaceutical Technology

OCTOBER 27, 2023

Lisaftoclax is under clinical development by Ascentage Pharma Group International and currently in Phase II for Chronic Lymphocytic Leukemia (CLL).

40

40

Pharmaceutical Technology

AUGUST 27, 2023

Lutetium (lu177) lilotomab satetraxetan is under clinical development by Thor Medical and currently in Phase II for B-Cell Chronic Lymphocytic Leukemia.

40

40

Pharmaceutical Technology

AUGUST 27, 2023

Lutetium (lu177) lilotomab satetraxetan is under clinical development by Thor Medical and currently in Phase II for B-Cell Chronic Lymphocytic Leukemia.

40

40

Pharmaceutical Technology

FEBRUARY 22, 2023

CMN-005 is under clinical development by CoImmune and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

40

40

Pharmaceutical Technology

MARCH 4, 2023

TRGFT-201 is under clinical development by Orca Biosystems and currently in Phase III for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Immunization 40

Immunization 40

Pharmaceutical Technology

FEBRUARY 26, 2023

Dezapelisib is under clinical development by Incyte and currently in Phase I for Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase I drugs for Chronic Lymphocytic Leukemia (CLL) have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.

Specialty Pharmacies 40

Specialty Pharmacies 40

Pharmaceutical Technology

FEBRUARY 27, 2023

Enzalutamide is under clinical development by Pfizer and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase I drugs for Relapsed Chronic Lymphocytic Leukemia (CLL) have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.

Immunization 40

Immunization Hospitals 40

Pharmaceutical Technology

FEBRUARY 14, 2023

Pevonedistat hydrochloride is under clinical development by Millennium Pharmaceuticals and currently in Phase I for Solid Tumor. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It is administered through intravenous route.

40

40

Pharmaceutical Technology

MAY 8, 2023

The approvals were granted for two Supplemental Applications to covert conditional approval to regular approval, and two Supplemental New Drug Applications to treat Waldenström’s macroglobulinemia (WM), and chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adult patients.

52

52

Pharmaceutical Technology

FEBRUARY 23, 2023

According to Globaldata, it is involved in 3 clinical trials, of which 1 was completed, and 2 are ongoing. The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. It is a new molecular entity.

Vaccines 40

Vaccines 40

Pharmaceutical Technology

FEBRUARY 27, 2023

Enzalutamide is under clinical development by Pfizer and currently in Phase I for Relapsed Multiple Myeloma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. EU, Japan and Asia-Pacific and hepatocellular carcinoma in the U.S, EU and Asia.

Immunization 45

Immunization Hospitals 45

European Pharmaceutical Review

FEBRUARY 8, 2023

Breyanzi sales will also be supplemented by the anticipated approval in chronic lymphocytic leukemia (CLL) in 2027, making it the first and only currently marketed CD19 CAR-T agent to penetrate the CLL market.

Labelling 97

Labelling Compounding 97

Pharmaceutical Technology

FEBRUARY 26, 2023

Dezapelisib is under clinical development by Incyte and currently in Phase I for Hairy Cell Leukemia. According to GlobalData, Phase I drugs for Hairy Cell Leukemia have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Incyte is headquartered in Wilmington, Delaware, the US.

Specialty Pharmacies 40

Specialty Pharmacies 40

Pharmaceutical Technology

FEBRUARY 27, 2023

Enzalutamide is under clinical development by Pfizer and currently in Phase I for Myelofibrosis. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. EU, Japan and Asia-Pacific and hepatocellular carcinoma in the U.S, EU and Asia.

Immunization 40

Immunization Hospitals 40

Pharmaceutical Technology

FEBRUARY 23, 2023

Buparlisib hydrochloride is under clinical development by Adlai Nortye Biopharma and currently in Phase II for Mantle Cell Lymphoma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Adlai Nortye is headquartered in Hangzhou, Zhejiang, China.

52

52

PharmaShots

FEBRUARY 10, 2023

LEO Pharma Reports P-III Trial (DELTA 2) Results of Delgocitinib for Chronic Hand Eczema Date: Feb 10, 2023 | Tags: LEO Pharma, Delgocitinib, Chronic Hand Eczema, Clinical Trial, P-III, DELTA 2 Trial GSK’s Jemperli (dostarlimab-gxly) Receives the US FDA’s Regular Approval for Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer (..)

FDA 40

FDA 40

PharmaShots

FEBRUARY 10, 2023

LEO Pharma Reports P-III Trial (DELTA 2) Results of Delgocitinib for Chronic Hand Eczema Date: Feb 10, 2023 | Tags: LEO Pharma, Delgocitinib, Chronic Hand Eczema, Clinical Trial, P-III, DELTA 2 Trial GSK’s Jemperli (dostarlimab-gxly) Receives the US FDA’s Regular Approval for Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer (..)

FDA 40

FDA 40

Pharmaceutical Technology

JANUARY 20, 2023

BeiGene has received marketing authorisations for Brukinsa (zanubrutinib) in Great Britain from the Medicines and Healthcare products Regulatory Agency (MHRA) to treat chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL).

52

52

PharmaShots

JUNE 16, 2023

Date: June 12, 2023 | Tags: Novartis, Chinook Therapeutics, Atrasentan, Zigakibart, BION-1301, IgA nephropathy, M&A, ~$3.5B Date: June 12, 2023 | Tags: Novartis, Chinook Therapeutics, Atrasentan, Zigakibart, BION-1301, IgA nephropathy, M&A, ~$3.5B

FDA 40

FDA Labelling 40

Pharmaceutical Technology

DECEMBER 11, 2022

Richter’s transformation (RT) is a rare blood cancer arising in up to 10% of patients with chronic lymphocytic leukemia (CLL) and presenting as aggressive lymphoma, typically as diffuse large B-cell lymphoma (DLBCL). billion for Calquence. GlobalData is the parent company of Pharmaceutical Technology.

Labelling 59

Labelling FDA 59

Pharmaceutical Technology

MARCH 1, 2023

Nedisertib is under clinical development by Merck and currently in Phase I for Neuroendocrine Tumors. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It is a new chemical entity. The drug candidate targets DNA-dependent protein kinase (DNA-PK).

40

40

Pharmaceutical Technology

MARCH 1, 2023

Nedisertib is under clinical development by Merck and currently in Phase I for Head And Neck Cancer Squamous Cell Carcinoma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It is a new chemical entity. Merck overview Merck, a subsidiary of E.

40

40

Pharmaceutical Technology

FEBRUARY 27, 2023

Givinostat is under clinical development by Italfarmaco and currently in Phase II for Myelofibrosis. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It is administered through the oral route as an oral suspension and hard gelatin capsule.

40

40

Pharmaceutical Technology

FEBRUARY 27, 2023

Givinostat is under clinical development by Italfarmaco and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Givinostat is a histone deacetylase inhibitor.

40

40

Pharmaceutical Technology

FEBRUARY 27, 2023

Givinostat is under clinical development by Italfarmaco and currently in Phase II for Myelofibrosis. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It is administered through the oral route as an oral suspension and hard gelatin capsule.

40

40

PharmaShots

MAY 5, 2023

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive EC’s Marketing Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease Date: May 05, 2023 | Tags: Chiesi Global Rare Diseases, Protalix BioTherapeutics, PRX-102, pegunigalsidase alfa, Fabry Disease, Regulatory, EC, Marketing Authorization Kinoxis Therapeutics (..)

FDA 40

FDA 40

PharmaShots

FEBRUARY 15, 2023

The one P-II trial results showed that the therapy was well-tolerated & provide a durable & clinical improvement in glycemic control over 96wks. In the (ALPINE) trial, superior ORR over ibrutinib, ORR (80.4% favorable cardiac safety profile with lower rates of AF/flutter (5.2%

FDA 40

FDA Insurance Coverage Adverse Reactions Insurance 40

The Checkup by Singlecare

DECEMBER 15, 2022

Chronic inflammation will eventually cause permanent damage to the joint tissue which can result in long-lasting pain and misshapenness. Both medications should be avoided in patients who are immunocompromised as dictated by low white blood cells, including lymphocytes. Greater than or equal to 100kg: 162 mg every week.

Immunization 52

Immunization Vaccines Dosage FDA 52

The FDA Law Blog

FEBRUARY 29, 2024

A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. Drug companies are still required to conduct studies to confirm the anticipated clinical benefit. That did not happen.

FDA 59

FDA Documentation 59

BuzzRx

OCTOBER 26, 2022

Leukemia is a cancer of blood cells and blood-forming tissues in the body, such as the bone marrow and lymphatic system. In people with leukemia, normal blood cells, usually white blood cells, start to grow uncontrolled. There are many different types of leukemia, some of which are more common in children and others in adults.

Immunization 52

Immunization Chemotherapy 52

Pharmaceutical Technology

AUGUST 12, 2022

They were first licensed for use in 2017 for two forms of blood cancer, acute lymphoblastic leukemia (ALL), and B-cell lymphoma (BCL). Each of these approved CAR-T cell therapies consist of cells derived from the patient’s blood and target cancer cells expressing B lymphocyte antigen CD19. billion in 2021 and is forecast to reach $2.4

Immunization 52

Immunization Chemotherapy Compounding 52

Pharmaceutical Technology

FEBRUARY 13, 2023

Due to the catalytic mechanism of action, PROTACs are stipulated to have clinical advantages in indications where degrading the whole protein is more therapeutically beneficial, where covalent inhibitors are insufficient to fully block the oncogenic functions of the target or may not be selective enough.

Dosage 59

Dosage Chemotherapy Compounding Immunization 59

pharmaphorum

JULY 2, 2021

The company’s lead product is STAR-LLD, a once-weekly transdermal and continuous subcutaneous formulation of lenalidomide for chronic lymphocytic leukemia (CLL) and multiple myeloma (MM), two of the most common blood cancers in the US. He was also encouraged by the CEO’s track record in the life sciences industry.

Chemotherapy 105

Chemotherapy 105

Pharmaceutical Technology

MARCH 2, 2023

Pembrolizumab is under clinical development by Merck and currently in Phase III for Bile Duct Cancer (Cholangiocarcinoma). Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It is administered through subcutaneous route.It

Chemotherapy 40

Chemotherapy FDA Vaccines Immunization 40

Pharmaceutical Technology

MARCH 21, 2023

The ongoing monthly CMO Moves series is outlining the relationship between pharmaceutical and biotech companies, and CMOs using recent news events and clinical trial catalysts. Clinical trial catalysts announced for select therapies from late January to late February and the CMOs contracted to manufacture the therapies.

Packaging 59

Packaging FDA Vaccines Labelling 59